deltatrials
Completed PHASE3 INTERVENTIONAL 4-arm NCT02696785

A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis (COAST-V)

A Multicenter, Randomized, Double-Blind, Active and Placebo-Controlled 16-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in bDMARD-Naive Patients With Radiographic Axial Spondyloarthritis

Sponsor: Eli Lilly and Company

Conditions Spondyloarthritis
Interventions Adalimumab Ixekizumab Placebo
Updated 21 times since 2017 Last updated: Oct 31, 2019 Started: May 2, 2016 Primary completion: Dec 8, 2017 Completion: Oct 17, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Spondyloarthritis, this trial is completed. The trial is conducted by Eli Lilly and Company and has accumulated 21 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Jun 2017 · 31 days · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Nov 2017 · 2 months · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Jun 2018 · 5 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Oct 2018 · 2 months · monthly snapshot~Oct 2018 – ~Nov 2018 · 31 days · monthly snapshot~Nov 2018 – ~Dec 2018 · 30 days · monthly snapshot~Dec 2018 – ~Dec 2019 · 12 months · monthly snapshot~Dec 2019 – ~Jan 2021 · 13 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

21 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Dec 2019 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 16 earlier versions

  1. Dec 2018 — Dec 2019 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Nov 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE3

  3. Oct 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE3

  4. Aug 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE3

  5. Jul 2018 — Aug 2018 [monthly]

    Active Not Recruiting PHASE3

  6. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE3

  7. Jan 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  8. Dec 2017 — Jan 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  9. Nov 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  10. Sep 2017 — Nov 2017 [monthly]

    Recruiting PHASE3

  11. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE3

  12. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  13. Jun 2017 — Jul 2017 [monthly]

    Recruiting PHASE3

  14. May 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

  15. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE3

  16. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE3

    First recorded

May 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Eli Lilly and Company
Data source: Eli Lilly and Company

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Berlin, Germany , Brno, Czechia , Colorado Springs, United States , Columbia, United States , Cumberland, United States , Denver, United States , Elizabethtown, United States , Gwangjin-gu, South Korea , Hagerstown, United States , Houston, United States and 17 more locations